By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


 

Daiichi Sankyo, Inc. 

U.S. Corporate Headquarters
Two Hilton Court
Parsippany  New Jersey  07054  U.S.A.
Phone: 973-944-2600 Fax: 973-359-2645


SEARCH JOBS

About Daiichi Sankyo, Inc.

Daiichi Sankyo Inc., headquartered in Parsippany, New Jersey, is the U.S. subsidiary of Tokyo-based Daiichi Sankyo Co., Ltd., which is a global pharmaceutical innovator.

The headquarters company was established in 2005 from the merger of two leading Japanese pharmaceutical companies. This integration created a more robust organization that allows for continuous development of novel drugs that enrich the quality of life for patients around the world.

A central focus of Daiichi Sankyo's research and development is cardiovascular disease, including therapies for dyslipidemia, hypertension, diabetes and acute coronary syndrome. Also important to the company is the discovery of new medicines in the areas of infectious diseases, cancer, bone and joint diseases, and immune disorders.


This div will be replaced



Key Statistics


Email:
Ownership: Public

Web Site: Daiichi Sankyo, Inc.
Employees: 3,000 in the U.S.
Symbol: 4568.t
 



Industry
Pharmaceutical


Collaborations

Eli Lilly 

ArQule, Inc. 

U3 Pharma 





Company News
Daiichi Sankyo, Inc. (4568.t) Launches New Formulation Of LIXIANA 60 mg Tablets (edoxaban) In Japan 12/8/2014 8:13:38 AM
Ambit Biosciences And Daiichi Sankyo, Inc. (4568.t) Announce Two Oral Presentations And One Poster Highlighting Quizartinib To Be Presented At The 56th Annual Meeting Of The American Society of Hematology 12/5/2014 1:18:12 PM
Charleston Laboratories, Inc. And Daiichi Sankyo, Inc. (4568.t) Initiate Two Phase 3 Clinical Trials On Charleston's Lead Product, CL-108 11/20/2014 9:56:05 AM
Daiichi Sankyo, Inc. (4568.t) And Ambit Biosciences Announce Results Of Tender Offer 11/11/2014 8:21:35 AM
FDA Panel Backs Daiichi Sankyo, Inc. (4568.t)'s New A-Fib Drug Savaysa 10/31/2014 5:56:26 AM
FDA Staff Recommends Limited Use Of Daiichi Sankyo, Inc. (4568.t)'s Blood Thinner Edoxaban 10/29/2014 6:32:32 AM
Center For Connected Health And Daiichi Sankyo, Inc. (4568.t) Sign Agreement To Co-Develop A Mobile App To Support Patients With Atrial Fibrillation 10/22/2014 9:01:01 AM
Perosphere Inc. And Daiichi Sankyo, Inc. (4568.t) Enter Into A Clinical Trial Collaboration Agreement For Phase 3 Studies Of PER977 To Investigate Reversal Of The Anticoagulant Activity Of The Investigational Factor Xa-Inhibitor Edoxaban 10/6/2014 10:28:29 AM
Daiichi Sankyo, Inc. (4568.t) Boosts Cancer Pipeline With $410 Million Ambit Biosciences Buy 9/29/2014 5:58:51 AM
Daiichi Sankyo, Inc. (4568.t) Receives Approval For Additional Indications Of LIXIANA┬« (Edoxaban) In Japan 9/26/2014 8:30:52 AM
12345678910...
//-->